Drug Profile
Huperzine A - Supernus Pharmaceuticals
Alternative Names: BIS-001; BIS-001ER; INS-001; SPN 817Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Harvard University
- Developer Biscayne Pharmaceuticals; Supernus Pharmaceuticals
- Class Alkaloids; Antiepileptic drugs; Neuroprotectants; Nootropics; Sesquiterpenes; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Epilepsy; Partial epilepsies
- No development reported Dravet syndrome
Most Recent Events
- 31 Dec 2023 Supernus Pharmaceuticals has patent pending for Huperzine A in USA and rest of the world
- 31 Dec 2023 Supernus Pharmaceuticals has patent protection for Huperzine A in USA, China and rest of the world
- 08 Nov 2023 Supernus Pharmaceuticals plans a phase IIb trial for Focal seizures (Treatment-resistant) in the second half of 2024